Introduction
Pathogenesis of MM is believed to occur as a multistep transformation process. In addition to genetic alterations, the bone marrow (BM) microenvironment has been reported to contribute substantially to growth and survival of MM. 1 It has been found that cells from the BM microenvironment, such as BM stromal cells, provide a number of cytokines that promote the growth of myeloma cells. 2, 3 Among these cytokines, IL-6 is considered as the major growth and survival factor for myeloma cells. [4] [5] [6] The findings that IL-6-gene deficient mice fail to develop plasma cell tumors, 7 that some of the MM cell lines are IL-6-dependent, and that IL-6 is a proliferative signal for primary MM explants 8, 9 led to the hypothesis that IL-6 is an essential growth and survival factor for multiple myeloma (MM).
The proliferative and survival-mediating effects of IL-6 are thought to be mediated by at least three intracellular signaling pathways, the Janus kinase/STAT3 (IL-6/gp130/STAT3), the Ras/ MAPK-extracellular signal regulated kinase 1,2 (ERK1,2) pathway and the PI3-K/AKT pathway. [10] [11] [12] Consistently, it has been demonstrated that inhibition of these pathways with either dominant-negative mutant proteins, antisense oligonucleotides or specific small compound kinase inhibitors impair proliferation or survival of MM cell lines in vitro. 11, 13, 14 However, many MM cell lines grow independently of IL-6 and IL-6 antagonists failed to induce remissions in patients with MM in phase-I clinical trials, questioning the singular role of IL-6 in MM. 15 In accordance with these observations we have recently demonstrated that in the presence of BM stromal cells MM cells survive independent of the IL-6/gp130/STAT3 pathway. 16 This indicates that additional factors provided by the BM microenvironment activate growth-regulating pathways, which might substitute for the antiapoptotic function of the IL-6/gp130/STAT3 pathway. The aim of this study was to investigate whether cytokines other than IL-6, which are present in the BM microenvironment, might activate growth-promoting pathways and contribute to proliferation and survival of MM cells. We particularly focused on cytokines, which might play a role in survival and proliferation of MM cells by affecting signaling pathways. These cytokines included IL-6, bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3 and SCF, which all have been reported to be secreted by MM cells and/or cells of the BM microenvironment. In addition, it has been demonstrated that corresponding receptors of these cytokines are expressed by MM cells and therefore these cytokines can play a role in MM. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Nevertheless, with exception of IL-6, the precise role of these cytokines in MM is still unclear.
Materials and methods

Cells and culture conditions
The human MM cell line MM.1S was kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA). RPMI-8226 human myeloma cells were obtained from the American Tissue Type Culture Collection (Manassas, VA, USA). Cells were cultured in RPMI 1640 medium (PAA-Laboratories, Linz, Austria) containing 10% fetal calf serum (FCS) and 2 mM L-glutamine.
Isolation of primary MM cells was performed as previously described. 29 In brief, mononuclear cells from bone marrow aspirates of MM patients were separated by Ficoll-Hypaque density gradient centrifugation, labeled with anti-CD138 paramagnetic beads and separated by MACS-columns (Miltenyi Biotech, Bergisch Gladbach, Germany). MM cells from 16 different patients were analyzed in this study (for patient characteristics see Table 1 ). Samples were taken from routine diagnostic specimens after informed consent of patients was obtained and permission was granted in accordance with the local ethics committee. 
Proliferation assay
MM.1S cells (6
Detection of apoptosis
In several pilot experiments we observed that a 3-day treatment with MEK1,2 or PI3-K inhibitors is an optimal time point to evaluate apoptosis of a proliferating cell line, whereas primary myeloma cells usually start to die between days 5 and 7 in culture. Therefore, we choose 7 days as the best time point to evaluate antiapoptotic effects of different cytokines. After 3 days (MM.1S cell line) or 7 days (primary MM cells) of treatment with either PI3-K inhibitor LY294002 (50 mM) or MEK inhibitor PD98059 (50 mM) (both from Cell Signaling Technology, Berverly, MA, USA), apoptosis was determined by annexin V-fluorescein isothiocyanate (FITC) staining according to the manufacturer's instructions (Bender MedSystems, Vienna, Austria) and analyzed by flow cytometry using a FACSCalibur flow cytometer and CELLQuest software (Becton Dickinson, Heidelberg, Germany). The fraction of annexin V-FITC positive cells was determined and expressed as percentage of untreated control cells. Similar to the condition of the proliferation assay, primary MM cells (10 6 /ml) were incubated with 100 ng/ml of either VEGF, LIF, SDF-1a, MIP1a, bFGF, SCF, IL-1b or IL-3 or 25 ng/ml of IL-6 in RPMI 1640 medium containing 2.5% FCS. After an incubation period of 7 days, cell survival was determined by Annexin V-FITC/ propidium iodide (PI) double staining. The percentage of viable cells, negative for both, Annexin V-FITC and PI, was determined.
Western blot analysis
To achieve maximal downregulation of constitutive pathway activation without affecting survival, MM.1S cells were starved overnight in RPMI 1640 medium with 1% FCS. Cells were washed three times to deplete serum completely. Incubation with PI3-K inhibitor wortmannin (1 mM or LY294002 (50 mM or MEK inhibitor PD98059 (50 mM (all from Cell Signaling Technology, Berverly, MA, USA) was performed for 1 h prior to the addition of cytokines in RPMI 1640 medium with 0% FCS. Incubation either with IL-6, bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3, SCF, IL-4, IL-11 (100 ng/ml), 10% FCS or 5 mg/ml BSA was performed for 15 min in RPMI 1640 medium without FCS. Cells were harvested, washed, and lysed in buffer containing 10 mM TRIS, 50 mM NaCl, Na-pyrophosphate, 1% Triton, 1 mM Na3VO4, 1 mM PMSF and protein inhibitor cocktail (Roche, Mannheim, Germany). Cell lysates were 
Statistical analyses
The statistical analyses were performed by means of an unpaired Student's t-test. The minimal level of significance was Po0.05. An asterisk indicates significance.
Results
Various bone marrow-derived cytokines induce PI3-K-dependent phosphorylation of AKT and FKHR in MM cells
We analyzed whether bone marrow-derived cytokines like IL-6, bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3 and SCF can activate the AKT pathway in MM cells. In addition, we tested IL-4 that so far is not known to directly affect myeloma cell growth. We also wanted to investigate whether IL-11, belonging to the IL-6-type cytokines family and binding together with IL-6 to gp130 receptor, 4, 30 Various cytokines induce activation of the MAPK-ERK1,2 pathway whereas the STAT3 pathway is exclusively activated by IL-6 or LIF Next, we investigated the capability of the above-described cytokines (IL-6, bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3, SCF, IL-11 or IL-4) to induce phosphorylation of ERK1,2 and STAT3 in MM.1S cells. In addition, we evaluated whether treatment of MM.1S cells with the MEK-specific inhibitor PD98059 prior to cytokine stimulation was able to abrogate cytokine-dependent ERK1,2 phosphorylation. Except IL-4 and 
No cross-talk between AKT, MAPK-ERK1,2 and STAT3 pathways
Several reports showed that ERK1,2 might be activated by a PI3-K stimulated cascade in some cell types, 31, 32 and therefore inhibition of PI3-K might prevent cytokine-dependent proliferation via downstream inhibitory effects on ERK1,2 activation. Thus, we compared the ability of PI3-K inhibitors and MEK inhibitor to inhibit ERK1,2, p70 S6K and STAT3 phosphorylation. Since STAT3 is not phosphorylated in the presence of 10% FCS, we treated cells with IL-6 to induce STAT3 phosphorylation. Treatment with the PI3-K inhibitor LY294002 had no effect on ERK1,2 ( Figure 3b ) and STAT3 activation (Figure 3e ) but completely inhibited phosphorylation of AKT (Figure 3a) as well as p70S6K (Figure 3c) . Similarly, the MEK inhibitor PD98059 could not inhibit phosphorylation of AKT (Figure 3a ), p70 S6K ( Figure 3c ) and STAT3 (Figure 3e ), indicating that phosphorylation of AKT (at Ser 473), p70 S6K (at Thr 389) and STAT3 is independent of the MEK/ERK1,2 pathway. Thus, inhibition of PI3-K and subsequently of AKT has no effect on ERK1,2 and STAT3 phosphorylation and inhibition of MEK/ERK1,2 has no effect on AKT and STAT3 activation in our model, suggesting independent activation of ERK1,2, STAT3 and AKT signaling pathways in MM.1S cells. MM.1S cells were treated with BSA 5 mg/ml, IL-6, IL-4 and IL-11 (100 ng/ml) for 15 min in RPMI 1640 medium without FCS. Pretreatment with LY294002 was performed as described above. Cell lysates were electrophoresed and immunoblotted with antiphospho-ERK1,2 ab and antiphospho-STAT3 ab. Western blot analysis of b-actin served as a control for all blots.
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Treatment with small compound inhibitors of the PI3-K/AKT or MEK/ERK1,2 pathway induces apoptosis in MM.1S and primary MM cells
After we had shown that various cytokines were able to activate the PI3-K/AKT and ERK1,2 pathways, we were interested in the biological effects of inhibitors of these pathways on MM cell lines and primary MM cells. Therefore, we treated the MM cell line MM.1S and primary MM cells freshly isolated from bone marrow aspirates with PI3-K specific inhibitor LY294002 (samples of five patients) and with MEK inhibitor PD98059 (samples of six patients). Treatment of MM.1S cells with LY 294002 led to a strong increase (Po0.001) of apoptotic cells from a mean of 10 to 57%, whereas treatment with PD98059 led to a moderate increase (Po0.001) to 23% (Figure 4a) . Treatment of primary MM cells with LY294002 led to a significant increase (P ¼ 0.003) of the apoptotic cell fraction from a median of 10% (range 8-32%) to 83% (range 41-91) (Figure 4b ). Treatment of primary MM cells with PD98059 significant increased (P ¼ 0.004) the apoptotic fraction up to 54% (range 29-78) compared to 22% (range 7-35) in control cells (Figure 4c ). Due to the limited number of primary MM cells we were not able to analyze both PD98059 and LY294002 in each patient sample.
To examine whether DMSO, used as a solvent (0.5%) for PD98059 and LY294002, has apoptotic effects on MM cells, we incubated MM1.S cells with DMSO for 3 days (same conditions as in Figure 4 ) and analyzed apoptotic cell fraction by FACS analyses. At concentration of 1% DMSO we measured 1.5% Annexin/PI positive cells compared to 1.4% Annexin V/ PI positive cells in 0% DMSO. Therefore, we conclude that DMSO 
Various cytokines induce proliferation of MM.1S and RPMI-8226 MM cells and promote survival of primary MM cells
The data presented above suggest that cytokine-induced activation of the PI3-K/AKT and ERK1,2 signaling pathways could be relevant for growth and survival of MM cells. Therefore, it was of interest to determine the effects of these cytokines on proliferation and survival of MM cells. To address this question, we first analyzed the effect of IL-6, bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3 or SCF on in vitro growth of MM.1S and RPMI-8226 MM cells. Treatment with these cytokines induced a significant increase of 3 H-thymidine incorporation in both MM.1S and RPMI-8226 cells compared to untreated control cells (Figure 5a, b) . In contrast, IL-4, IL-11 and also BSA, which was used as control, had no impact on proliferation of MM cells (Figure 5c ).
Furthermore, we were interested to analyze the effect of IL-6, bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3 or SCF on the survival of primary MM cells (patient 1,5,10,11,13-16). Therefore, freshly isolated MM cells from eight different patients were cultured for 7 days and percentage of viable cells was determined by annexin V/PI staining. All cytokines (Po0.05) except IL-1b (P ¼ 0.1) were able to partially protect primary MM cells from apoptosis to a different extent. The median cell viability of eight patients with and without cytokine treatment is summarized in Figure 6 .
Discussion
Although IL-6 has been reported to be a crucial growth factor for MM cells, many MM cell lines grow independently of IL-6 and clinical trials with anti-IL-6 antibodies have so far failed to induce objective remissions in MM patients. 15 This suggests that cytokines other than IL-6 trigger IL-6/gp130/STAT3-independent growth-promoting pathways and prevent apoptosis in MM cells. Therefore, in a comparative analysis, we investigated the ability of other cytokines to activate signaling pathways relevant for MM.
Our data suggest that more cytokines than so far described are able to activate ERK1,2 and AKT signaling pathways and promote proliferation and survival of MM cells. LIF, like IL-6, binds to the gp130/a-chain of the IL-6 receptor and stimulates proliferation of MM cells. 27, 28 VEGF promotes proliferation and migration of MM cells. 17 Both VEGF and bFGF stimulate angiogenesis and elevated levels in the plasma of MM patients have been reported. 18, 20 MIP-1a has been shown to induce proliferation and migration in MM cell lines and to activate human osteoclasts. Elevated levels have been found in the bone marrow of MM patients, suggesting that this cytokine could be involved in the development of osteolytic lesions in MM. 21, 33 IL-1b induces osteoclast activating factor, 24 ,25 IL-6 production and upregulates adhesion molecules in MM cells. 34 SDF-1a modulates VLA-4 dependent MM cell adhesion and has been demonstrated to be involved in plasma cell migration. 22, 35 SCF ligand and receptor are expressed by MM cells 36 and show abnormal expression in MM bone marrow mesenchymal progenitor cells (MPC) in comparison to normal MPC. IL-3 stimulates DNA synthesis in different MM cell lines 37 and is involved in the differentiation of peripheral blood nonadherent mononuclear cells into mature plasma cells.
Here we have shown that in addition to IL-6, also bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3 and SCF can induce activation of the ERK1,2 and PI3-K/Akt pathway in MM.1S cells. Further we observed that these cytokines significantly stimulated proliferation of MM cell lines and prolonged the survival of primary MM cells freshly isolated from BM aspirates, suggesting that these cytokines mediate proliferation and survival via activation of the PI3-K/AKT and ERK1,2 signaling pathways. However, it is conceivable that bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3 and SCF might act indirectly by inducing the expression of IL-6. Due to the fact that these cytokines do not induce STAT-3 phosphorylation, whereas we and others have shown that IL-6 leads to STAT-3 phosphorylation, it is not likely that bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3 and SCF act via induction of IL-6 and the subsequent activation of IL-6/gp130/STAT3 pathway. As a control we used IL-4 and IL-11, which are not able to activate the PI3-K/AKT, ERK1,2 and STAT3 pathways and subsequently did not stimulate proliferation of MM cells. Interestingly, IL-11 that binds, like IL-6 and LIF, to the common signal transducing receptor chain gp130 38 did not activate STAT3 pathway, suggesting that not all gp130 binding cytokines activate STAT3 pathway in our model.
Thus, this study demonstrates that in MM cells the growth and survival promoting ERK1,2 and AKT pathways can be independently activated by an extended number of cytokines. Our observation that, except IL-6 and LIF, all cytokines analyzed in this study fail to activate STAT3 clearly indicates that in our model growth factor mediated proliferation or survival is not achieved via the induction of IL-6 or the IL-6/gp130/STAT3 pathway. This is consistent with our previous findings indicating that IL-6/gp130/STAT3 is not essential for the survival of MM cells if they grow in the presence of cells from the bone marrow microenvironment. 16 Other cytokines, which in addition to those analyzed in our study, have been characterized as growth factors in MM are IGF-1, 39 IL-10, 40 IL-15, 41 IL-21, 42 and hepatocyte growth factor. 43 Thus, it appears that there is a high redundancy in support for growth and survival for MM cells provided in the BM microenvironment. Our own observations, and reports from the literature, support the idea that the growth/survival signals of various environment-derived factors might converge on just a few growth promoting intracellular signaling pathways. Therefore, blocking these pathways rather than blocking a single factor such as IL-6 might be a promising approach for the development of novel treatment strategies for MM. In accordance with this hypothesis, we could demonstrate that inhibition of either the MEK/ERK1,2 or the AKT pathway with the small compound inhibitors PD98059 and LY294002 induces cell death in the MM cell line MM.1S. This is consistent with previously published data demonstrating that inhibition of these pathways inhibits growth of MM cell lines in vitro, [12] [13] [14] 44 Here, we demonstrate for the first time that small compound inhibition of MEK/ERK1,2 or AKT does not only induce apoptosis in MM cell lines but also in primary MM cells freshly isolated from bone marrow aspirates underpinning the importance of these pathways for malignant growth of MM.
A more detailed pathway analysis revealed that the cytokines employed in this study not only trigger the phosphorylation of ERK1,2 and AKT but also of FKHR. The latter proteins require Figure 6 Effects of different cytokines (IL-6, bFGF, IL-1b, MIP-1a, LIF, VEGF, SDF-1a, IL-3 and SCF) on the survival of primary human MM cells. Primary MM cells freshly isolated from routine diagnostic bone marrow aspirates of eight patients (patient 1,5,10,11,13-16) (for patient characteristics see Table 1 ) were cultured with different cytokines (100 ng/ml, IL-6 25 ng/ml) in RPMI 1640 medium containing 2.5% FCS. After an incubation period of 7 days, cell survival was analyzed by annexin V-FITC/PI staining and subsequent flow cytometry analysis. The median of fraction of viable cells (annexin V/PI negative) for all patients was determined. Data represent median values with standard deviations. An asterisk indicates significance (Student's t-test). Multitude of cytokines triggers signaling cascades in MM S Lentzsch et al active PI3-K and are involved in the activation of antiapoptotic pathways. 45, 46 In addition, we have found that treatment with the PI3-K inhibitor completely inhibits phosphorylation of AKT and FKHR at Ser 256, but had no effect on ERK1,2 phosphorylation. On the other hand, treatment with the MEK inhibitor PD98059 blocked ERK1,2 activation but did not inhibit phosphorylation of AKT or FKHR, supporting the idea that the MEK/ERK1,2 and PI3-K/AKT pathways do not cross-talk, and therefore might contribute independently to growth and survival of MM cells.
In summary, we have shown for the first time that more cytokines than so far described redundantly stimulate the MEK/ ERK1,2 and the PI3-K/AKT/FKHR pathway and promote proliferation of MM cell lines and survival of primary MM cells. Thereby, we provide evidence that the MEK/ERK1,2 and PI3-K/ AKT/FKHR pathway might contribute independently to the malignant growth of MM cells and inhibition of such intracellular pathways could be a promising approach for the development of novel treatment strategies in MM.
